加替沙星、左氧氟沙星序贯治疗下呼吸道感染的药物经济学评价

目的：评价加替沙星静脉滴注和加替沙星静脉滴注与左氧氟沙星口服序贯治疗下呼吸道感染的成本-效果,为临床制定合理用药方案提供参考。方法：将256例下呼吸道感染患者随机分为2组,其中对照组应用加替沙星注射液400mg静脉滴注,qd;序贯组用加替沙星注射液400mg静脉滴注qd,3d后改为口服左氧氟沙星片400mg,qd,疗程均为7～14d,观察两组的临床疗效,并进行成本-效果分析。结果：2组在临床疗效、细菌学清除率及不良反应发生率方面差异无统计学意义（P〉0.05）,但对照组的费用却显著高于序贯治疗组（P〈0.05）。结论：加替沙星、左氧氟沙星序贯治疗下呼吸道感染具有与单用加替沙星静脉滴注相似的临床疗效,但比单用更具经济学意义,是治疗下呼吸道感染的经济合理方案。

Sequential Therapy of Gatifloxacin and Levofloxacin for Lower Respiratory Tract Infections:Pharmacoeconomic Analysis

OBJECTIVE：To evaluate the pharmacoeconomic efficacy of sequential therapy of gatifloxacin and levofloxacin in the treatment of lower respiratory tract infections（LRTI） for references of rational drug use in the clinical practice. METHODS：A total of 256 inpatients with LRTI were randomized to two groups：the control group was assigned to receive gatifloxacin injection 400mg by iv gtt q.d,while the treatment group（sequential group） to receive gatifloxacin injection 400mg q.d for 3 days followed by oral levofloxacin 400mg q.d.The course of treatment was 7～14 days in both group.Clinical efficacy in two groups was observed and cost-effectiveness analysis was made after the treatment.RESULTS：There were no significant difference between two groups in effective rate,germ-clearance rates and incidence of ADRs（P〉0.05）,but the cost in the control group was significantly higher than in sequential group（P〈0.05）.CONCLUSION：The sequential therapy of gatifloxacin and levofloxacin is equivalent to gatifloxacin alone in clinical efficacy,but is superior to the latter one in cost-effectiveness,which turned out to be an economic and reasonable therapy for lower respiratory tract infections.